Benitec Biopharma Inc reports results for the quarter ended in December - Earnings Summary

Benitec Biopharma

13/02/2024 14:01

* Benitec Biopharma Inc  BNTC.OQ  reported a quarterly
adjusted
loss of $2.64​​ per share for the quarter ended in December,
higher than the same quarter last year, when the company
reported EPS of $-3.40.  The lone analyst forecast for the
quarter was for a loss of 39 cents per share. 
    * Reported revenue was zero​; analysts expected zero. 
    * Benitec Biopharma Inc's reported EPS for the quarter was a
loss
of $2.64​.
    * Benitec Biopharma Inc shares had fallen by 11.8% this
quarter.

FORECAST CHANGES
    * The mean earnings estimate of analysts was unchanged in
the last
three months.​ 
    * In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company.

RECOMMENDATIONS
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 1 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell." 
    * Wall Street's median 12-month price target for Benitec
Biopharma
Inc is $8.00 

This summary was machine generated from LSEG data February 13 at
02:01 p.m. UTC. ​All figures in US dollars unless otherwise
stated. (For questions concerning the data in this report,
contact Estimates.Support@lseg.com. For any other questions or
feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Dec. 31 2023      -0.39          -2.64          Missed
 Sep. 30 2023      -0.51          -2.76          Missed
 Jun. 30 2023      -3.23          -2.83          Beat
 Mar. 31 2023      -3.40          -2.72          Beat